Antibe Therapeutics Inc(Pre-Merger) ATBPF

Healthcare

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.

GREY:ATBPF - Post by User

Antibe Therapeutics Inc(Pre-Merger) > This stock has dropped the whole year

<< Previous

Bullboard Posts

Next >>

Comment by cashcrabon Dec 20, 2020 4:58pm

166 Views

Post# 32149787

RE:RE:This stock has dropped the whole year

keep in mind this is 2020 we are looking at. Plenty of stocke have been down all year. Traders have been running up tech stocks. If Antibe were to establish an uptrend, people would jump in and begin the run up Im sure this will happen but it is taking longer than I thought. Im holding untill it reaches 1b market cap and possibly longer

<< Previous

Bullboard Posts

Next >>

NervGen: Are amazing human trial results leaking out?